Boston Scientific (NYSE:BSX) Releases FY 2025 Earnings Guidance

Boston Scientific (NYSE:BSX - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.870-2.940 for the period, compared to the consensus earnings per share estimate of 2.860. The company issued revenue guidance of $19.3 billion-$19.6 billion, compared to the consensus revenue estimate of $19.1 billion. Boston Scientific also updated its Q2 2025 guidance to 0.710-0.730 EPS.

Boston Scientific Stock Up 1.5 %

Shares of NYSE:BSX opened at $94.96 on Wednesday. The company has a market capitalization of $140.45 billion, a P/E ratio of 75.97, a P/E/G ratio of 2.79 and a beta of 0.73. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock's fifty day simple moving average is $99.00 and its 200-day simple moving average is $94.55. Boston Scientific has a 52-week low of $67.80 and a 52-week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, equities research analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research note on Friday, January 10th. Morgan Stanley raised their price target on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Barclays upped their price target on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Truist Financial lowered their target price on Boston Scientific from $120.00 to $113.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Finally, Argus set a $130.00 price objective on Boston Scientific in a research note on Tuesday, February 18th. One research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $110.22.

Insider Buying and Selling at Boston Scientific

In related news, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the transaction, the senior vice president now directly owns 36,193 shares of the company's stock, valued at $3,441,592.37. This represents a 11.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares of the company's stock, valued at $560,103.60. This trade represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 138,009 shares of company stock worth $14,407,381 over the last quarter. Corporate insiders own 0.50% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

An institutional investor recently raised its position in Boston Scientific stock. Brighton Jones LLC raised its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 0.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,376 shares of the medical equipment provider's stock after acquiring an additional 226 shares during the quarter. Brighton Jones LLC's holdings in Boston Scientific were worth $2,445,000 as of its most recent filing with the Securities & Exchange Commission. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.